Bayesian hierarchical modeling based on multisource exchangeability

&NA; Bayesian hierarchical models produce shrinkage estimators that can be used as the basis for integrating supplementary data into the analysis of a primary data source. Established approaches should be considered limited, however, because posterior estimation either requires prespecification of a shrinkage weight for each source or relies on the data to inform a single parameter, which determines the extent of influence or shrinkage from all sources, risking considerable bias or minimal borrowing. We introduce multisource exchangeability models (MEMs), a general Bayesian approach for integrating multiple, potentially non‐exchangeable, supplemental data sources into the analysis of a primary data source. Our proposed modeling framework yields source‐specific smoothing parameters that can be estimated in the presence of the data to facilitate a dynamic multi‐resolution smoothed estimator that is asymptotically consistent while reducing the dimensionality of the prior space. When compared with competing Bayesian hierarchical modeling strategies, we demonstrate that MEMs achieve approximately 2.2 times larger median effective supplemental sample size when the supplemental data sources are exchangeable as well as a 56% reduction in bias when there is heterogeneity among the supplemental sources. We illustrate the application of MEMs using a recently completed randomized trial of very low nicotine content cigarettes, which resulted in a 30% improvement in efficiency compared with the standard analysis.

[1]  Jonathan French,et al.  Using Historical Data With Bayesian Methods in Early Clinical Trial Monitoring , 2012 .

[2]  Suhail A R Doi,et al.  Meta-analysis of heterogeneous clinical trials: an empirical example. , 2011, Contemporary clinical trials.

[3]  Gene Pennello,et al.  Experience with Reviewing Bayesian Medical Device Trials , 2007, Journal of biopharmaceutical statistics.

[4]  A. Raftery Bayesian Model Selection in Social Research , 1995 .

[5]  D. Sargent,et al.  Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  D. Hatsukami,et al.  Reduced nicotine content cigarettes: effects on toxicant exposure, dependence and cessation. , 2010, Addiction.

[7]  Jason A. Oliver,et al.  Reducing nicotine exposure results in weight gain in smokers randomised to very low nicotine content cigarettes , 2016, Tobacco Control.

[8]  D. Madigan,et al.  Bayesian Model Averaging for Linear Regression Models , 1997 .

[9]  Robert E. Kass,et al.  A default conjugate prior for variance components in generalized linear mixed models (comment on article by Browne and Draper) , 2006 .

[10]  Edward S. Kim,et al.  Bayesian adaptive design for targeted therapy development in lung cancer — a step toward personalized medicine , 2008, Clinical trials.

[11]  M. al’Absi,et al.  Effects of 6-Week Use of Reduced-Nicotine Content Cigarettes in Smokers With and Without Elevated Depressive Symptoms , 2017, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[12]  Nan Chen,et al.  Phase II trial design with Bayesian adaptive randomization and predictive probability , 2012, Journal of the Royal Statistical Society. Series C, Applied statistics.

[13]  P. Green Reversible jump Markov chain Monte Carlo computation and Bayesian model determination , 1995 .

[14]  Jason D. Robinson,et al.  Randomized Trial of Reduced-Nicotine Standards for Cigarettes. , 2015, The New England journal of medicine.

[15]  A. Raftery,et al.  Default Priors and Predictive Performance in Bayesian Model Averaging, with Application to Growth Determinants , 2007 .

[16]  M. A. Best Bayesian Approaches to Clinical Trials and Health‐Care Evaluation , 2005 .

[17]  Arto Luoma,et al.  Bayesian Model Selection , 2016 .

[18]  Rachel S. G. Sealfon,et al.  Clinical illness and outcomes in patients with Ebola in Sierra Leone. , 2014, The New England journal of medicine.

[19]  Gordon Graham,et al.  Bayesian sample size for exploratory clinical trials incorporating historical data , 2008, Statistics in medicine.

[20]  Brian P Hobbs,et al.  Adaptive adjustment of the randomization ratio using historical control data , 2013, Clinical trials.

[21]  D J Spiegelhalter,et al.  Bayesian approaches to random-effects meta-analysis: a comparative study. , 1995, Statistics in medicine.

[22]  D. Rubin,et al.  Inference from Iterative Simulation Using Multiple Sequences , 1992 .

[23]  Steven N Goodman,et al.  A Bayesian approach to randomized controlled trials in children utilizing information from adults: the case of Guillain-Barre , 2005, Clinical trials.

[24]  Bill Ravens,et al.  An Introduction to Copulas , 2000, Technometrics.

[25]  Keming Yu,et al.  Bayesian Mode Regression , 2012, 1208.0579.

[26]  M. Daniels A prior for the variance in hierarchical models , 1999 .

[27]  D. Hatsukami,et al.  Biochemical Estimation of Noncompliance with Smoking of Very Low Nicotine Content Cigarettes , 2014, Cancer Epidemiology, Biomarkers & Prevention.

[28]  Ajay Jasra,et al.  Markov Chain Monte Carlo Methods and the Label Switching Problem in Bayesian Mixture Modeling , 2005 .

[29]  Michael A Proschan,et al.  Design of a Randomized Controlled Trial for Ebola Virus Disease Medical Countermeasures: PREVAIL II, the Ebola MCM Study. , 2016, The Journal of infectious diseases.

[30]  Tony Tse,et al.  Terminated Trials in the ClinicalTrials.gov Results Database: Evaluation of Availability of Primary Outcome Data and Reasons for Termination , 2015, PloS one.

[31]  P. Horby,et al.  Randomised controlled trials for Ebola: practical and ethical issues , 2014, The Lancet.

[32]  Brian Neelon,et al.  Bayesian Analysis Using Power Priors with Application to Pediatric Quality of Care , 2010 .

[33]  William J. Browne,et al.  Bayesian and likelihood-based methods in multilevel modeling 1 A comparison of Bayesian and likelihood-based methods for fitting multilevel models , 2006 .

[34]  Bradley P Carlin,et al.  Hierarchical Commensurate and Power Prior Models for Adaptive Incorporation of Historical Information in Clinical Trials , 2011, Biometrics.

[35]  Thierry Roncalli,et al.  Which Copula is the Right One? , 2000 .

[36]  Bradley P Carlin,et al.  Commensurate Priors for Incorporating Historical Information in Clinical Trials Using General and Generalized Linear Models. , 2012, Bayesian analysis.

[37]  P. Green,et al.  Reversible jump MCMC , 2009 .

[38]  Arnovst Kom'arek,et al.  Clustering for multivariate continuous and discrete longitudinal data , 2013, 1304.4448.

[39]  P. Müller,et al.  Determining the Effective Sample Size of a Parametric Prior , 2008, Biometrics.

[40]  B. Carlin,et al.  Semiparametric Bayesian commensurate survival model for post‐market medical device surveillance with non‐exchangeable historical data , 2014, Biometrics.

[41]  Karel G M Moons,et al.  Incorporation of historical data in the analysis of randomized therapeutic trials. , 2011, Contemporary clinical trials.

[42]  Jean-Michel Marin,et al.  Bayesian Modelling and Inference on Mixtures of Distributions , 2005 .

[43]  K. Karwowska,et al.  Ebola virus disease , 2019, The Lancet.

[44]  P. Thall,et al.  Statistical controversies in clinical research: scientific and ethical problems with adaptive randomization in comparative clinical trials. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[45]  J. Ioannidis,et al.  Non-randomised Ebola trials--lessons for optimal outbreak research. , 2016, The Lancet. Infectious diseases.

[46]  Guidance for Industry E 10 Choice of Control Group and Related Issues in Clinical Trials , 2001 .

[47]  P. Thall,et al.  Practical Bayesian adaptive randomisation in clinical trials. , 2007, European journal of cancer.

[48]  Michael A Proschan,et al.  Statistical considerations for a trial of Ebola virus disease therapeutics , 2016, Clinical trials.

[49]  Jing Ning,et al.  Response‐adaptive randomization for clinical trials with adjustment for covariate imbalance , 2010, Statistics in medicine.

[50]  D. Spiegelhalter,et al.  Summarizing historical information on controls in clinical trials , 2010, Clinical trials.

[51]  J. Ibrahim,et al.  Power prior distributions for regression models , 2000 .

[52]  D J Spiegelhalter,et al.  Bayesian methods for cluster randomized trials with continuous responses. , 2001, Statistics in medicine.

[53]  Adrian E. Raftery,et al.  Bayesian Model Averaging: A Tutorial , 2016 .

[54]  R. Kass,et al.  Reference Bayesian Methods for Generalized Linear Mixed Models , 2000 .

[55]  M. Steel,et al.  Benchmark Priors for Bayesian Model Averaging , 2001 .

[56]  J. Koopmeiners,et al.  Estimations and predictors of non-compliance in switchers to reduced nicotine content cigarettes. , 2016, Addiction.

[57]  D. Spiegelhalter,et al.  Bayesian Approaches to Clinical Trials and Health-Care Evaluation: Spiegelhalter/Clinical Trials and Health-Care Evaluation , 2004 .

[58]  Joseph S Koopmeiners,et al.  Estimating causal effects from a randomized clinical trial when noncompliance is measured with error. , 2018, Biostatistics.

[59]  S J Pocock,et al.  The combination of randomized and historical controls in clinical trials. , 1976, Journal of chronic diseases.

[60]  J. Koopmeiners,et al.  Nicotine and Anatabine Exposure from Very Low Nicotine Content Cigarettes. , 2016, Tobacco Regulatory Science.

[61]  D. Spiegelhalter,et al.  Disease Mapping With WinBUGS and MLwiN, Bayesian Approaches to Clinical Trials and Health Care Evaluation , 2004 .

[62]  Adrian E. Raftery,et al.  Bayesian model averaging: a tutorial (with comments by M. Clyde, David Draper and E. I. George, and a rejoinder by the authors , 1999 .

[63]  Fulvio De Santis,et al.  Power Priors and Their Use in Clinical Trials , 2006 .

[64]  M. Stephens Dealing with label switching in mixture models , 2000 .

[65]  M. al’Absi,et al.  Reduced Nicotine Content Cigarettes and Nicotine Patch , 2013, Cancer Epidemiology, Biomarkers & Prevention.

[66]  J. York,et al.  Bayesian Graphical Models for Discrete Data , 1995 .

[67]  Joseph G Ibrahim,et al.  Bayesian Design of Noninferiority Trials for Medical Devices Using Historical Data , 2011, Biometrics.

[68]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[69]  A. Gelman Prior distributions for variance parameters in hierarchical models (comment on article by Browne and Draper) , 2004 .

[70]  John M. Olin Calculating posterior distributions and modal estimates in Markov mixture models , 1996 .

[71]  D. Berry,et al.  Adaptive assignment versus balanced randomization in clinical trials: a decision analysis. , 1995, Statistics in medicine.